机构：[1]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology,Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Pathology, Fudan University, Shanghai, China[4]The Cancer of Unknown Primary Group of Pathology Committee, Chinese Research Hospital Association, Shanghai, China[5]Department of Pathology, Chengdu Second People’s Hospital, Chengdu, China[6]Department of Pathology, ChongqingUniversity Cancer Hospital, Chongqing, China[7]The Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd.,Hangzhou, China[8]Department of Pathology, Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[9]Department of Pathology, Sir RunRun Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China[10]Department of Pathology, Hubei CancerHospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[11]The Institute of MachineLearning and Systems Biology, College of Electronics and Information Engineering, Tongji University, Shanghai, China[12]Xuzhou Engineering Research Center of Medical Genetics and Transformation, Department of Genetics, Xuzhou MedicalUniversity, Xuzhou, China[13]Department of Pathology, National Clinical Research Center of Cancer, Key Laboratory ofCancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute andHospital, Tianjin, China[14]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
Background Liver metastases (LM) are the most common tumors encountered in the liver and continue to be a significant cause of morbidity and mortality. Identification of the primary tumor of any LM is crucial for the implementation of effective and tailored treatment approaches, which still represents a difficult problem in clinical practice.</p> Methods The resection or biopsy specimens and associated clinicopathologic data were archived from seven independent centers between January 2017 and December 2020. The primary tumor sites of liver tumors were verified through evaluation of available medical records, pathological and imaging information. The performance of a 90-gene expression assay for the determination of the site of tumor origin was assessed.</p> Result A total of 130 LM covering 15 tumor types and 16 primary liver tumor specimens that met all quality control criteria were analyzed by the 90-gene expression assay. Among 130 LM cases, tumors were most frequently located in the colorectum, ovary and breast. Overall, the analysis of the 90-gene signature showed 93.1% and 100% agreement rates with the reference diagnosis in LM and primary liver tumor, respectively. For the common primary tumor types, the concordance rate was 100%, 95.7%, 100%, 93.8%, 87.5% for classifying the LM from the ovary, colorectum, breast, neuroendocrine, and pancreas, respectively.</p> Conclusion The overall accuracy of 93.8% demonstrates encouraging performance of the 90-gene expression assay in identifying the primary sites of liver tumors. Future incorporation of the 90-gene expression assay in clinical diagnosis will aid oncologists in applying precise treatments, leading to improved care and outcomes for LM patients.</p>
基金：
Innovation Program of Shanghai Science and Technology Committee [20Z11900300]; Innovation Group Project of Shanghai Municipal Health Commission [2019CXJQ03]; Shanghai Science and Technology Development Fund [19MC1911000]; Shanghai Municipal Key Clinical Specialty grants [shslczdzk01301]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81,401,963, YJYQ201603]; Fudan University Shanghai Cancer Center grant [WJ2019H124]; Health commission of Hubei Province scientific research project [2020CFB869]; Hubei science and technology program [20Z11900300]; Canhelp Genomics Co., Ltd.; [81,972,728]
第一作者机构：[1]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology,Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Pathology, Fudan University, Shanghai, China[4]The Cancer of Unknown Primary Group of Pathology Committee, Chinese Research Hospital Association, Shanghai, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology,Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Pathology, Fudan University, Shanghai, China[4]The Cancer of Unknown Primary Group of Pathology Committee, Chinese Research Hospital Association, Shanghai, China[10]Department of Pathology, Hubei CancerHospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[13]Department of Pathology, National Clinical Research Center of Cancer, Key Laboratory ofCancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute andHospital, Tianjin, China
推荐引用方式(GB/T 7714)：
Wang Qifeng,Li Fen,Jiang Qingming,et al.Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.725988.
APA：
Wang, Qifeng,Li, Fen,Jiang, Qingming,Sun, Yifeng,Liao, Qiong...&Zhou, Xiaoyan.(2021).Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study.FRONTIERS IN ONCOLOGY,11,
MLA：
Wang, Qifeng,et al."Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study".FRONTIERS IN ONCOLOGY 11.(2021)
